SOUTH SAN FRANCISCO, Calif.,
Sept. 2, 2021 /PRNewswire/ -- Rigel
Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that
Raul Rodriguez, the company's
president and chief executive officer, and Dean Schorno, the company's chief financial
officer, will participate in the following virtual investor
conferences in September:
Citi's 16th Annual Biopharma Conference
(September 8-10, 2021)
- Raul Rodriguez will participate
in a panel discussion entitled: "Sickle Cell, Beta-Thal, ITP
& PKD - Measuring Industry Progress in Benign Hematology"
on Friday, September 10th
at 12:30 p.m. ET.
H.C. Wainwright 23rd Annual Global Investment
Conference (September 13-15,
2021)
- Dean Schorno will present a
company overview, which will be available for on-demand viewing for
conference attendees starting on Monday,
September 13th at 7:00
a.m. ET.
Cantor Fitzgerald Global Healthcare Conference (September 27-30, 2021)
- Raul Rodriguez will present a
company overview on Tuesday, September
28th at 4:40 p.m.
ET.
To access the live webcast of the Citi Annual Biopharma
Conference panel and the Cantor Fitzgerald Global Healthcare
Conference presentation, go to the Investor Relations section of
the company's website at www.rigel.com. Please connect to Rigel's
website several minutes prior to the start of the live webcast to
ensure adequate time for any software download that may be
necessary.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc., is a biotechnology company dedicated to discovering,
developing, and providing novel small molecule drugs that
significantly improve the lives of patients with hematologic
disorders, cancer, and rare immune diseases. Rigel's pioneering
research focuses on signaling pathways that are critical to disease
mechanisms. The company's first FDA-approved product is
TAVALISSE® (fostamatinib disodium hexahydrate)
tablets, the only oral spleen tyrosine kinase (SYK) inhibitor for
the treatment of adult patients with chronic immune
thrombocytopenia who have had an insufficient response to a
previous treatment. The product is also commercially available in
Europe (TAVLESSE) and Canada (TAVALISSE) for the treatment of
chronic immune thrombocytopenia in adult patients.
Fostamatinib is currently being studied in a Phase 3 clinical
trial (NCT03764618) for the treatment of warm autoimmune hemolytic
anemia (wAIHA)1; a Phase 3 clinical trial (NCT04629703)
for the treatment of hospitalized high-risk patients with
COVID-191; an NIH/NHLBI-sponsored Phase 3 ACTIV-4 Host
Tissue Study for the treatment of COVID-19 in hospitalized patients
on oxygen therapy, and a Phase 2 clinical trial for the treatment
of COVID-19 being conducted by Imperial College London.
Rigel's other clinical programs include its interleukin
receptor-associated kinase (IRAK) inhibitor program, and a
receptor-interacting serine/threonine-protein kinase (RIP1)
inhibitor program in clinical development with partner Eli Lilly
and Company. In addition, Rigel has product candidates in
development with partners AstraZeneca, BerGenBio ASA, and Daiichi
Sankyo.
For further information, visit www.rigel.com or follow
us on Twitter or LinkedIn.
Please see www.TAVALISSE.com for the full Prescribing
Information.
1The product for this use or indication is
investigational and has not been proven safe or effective by any
regulatory authority.
Investor Contact:
Jodi Sievers
Rigel Pharmaceuticals, Inc.
Phone: 650.624.1232
Email: ir@rigel.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/rigel-to-participate-in-three-upcoming-investor-conferences-301368021.html
SOURCE Rigel Pharmaceuticals, Inc.